IMNN Imunon, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 749647 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-4.9%
TTM EPS YoY60.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-448.6%
ROA-143.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets78.2%
Debt / equity0.00x
Current ratio1.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.79M | $1.46M | $2.34M | $2.49M | $1.90M | $1.23M | $2.17M | $2.23M |
| SG&A expense | $1.66M | $1.33M | $1.97M | $1.77M | $1.58M | $1.54M | $1.98M | $1.91M |
| Operating income | -$3.45M | -$2.79M | -$4.31M | -$4.26M | -$3.48M | -$2.77M | -$4.15M | -$4.15M |
| Interest expense | $264,133 | $77,273 | — | — | — | — | — | — |
| Net income | -$3.75M | -$2.81M | -$4.25M | -$4.22M | -$3.43M | -$2.74M | -$4.10M | -$4.06M |
| EBITDA | -$3.38M | -$2.72M | -$4.24M | -$4.19M | -$3.40M | -$2.69M | -$4.08M | -$4.11M |
| EPS (basic) | -0.64 | -0.54 | -0.84 | — | -1.16 | -2.15 | -3.15 | — |
| EPS (diluted) | -0.64 | -0.54 | -0.84 | — | -1.16 | -2.15 | -3.15 | — |
| Weighted avg. shares (diluted) | 5.95M | 5.23M | 5.03M | — | 2.94M | 1.28M | 1.30M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.04M | $6.86M | $4.79M | $8.78M | $5.25M | $4.73M | $2.87M | $5.87M |
| Current assets | $5.84M | $8.69M | $6.62M | $10.72M | $7.26M | $6.89M | $5.09M | $8.01M |
| PP&E, net | $393,696 | $459,016 | $459,936 | $529,936 | $601,425 | $676,565 | $734,243 | $541,272 |
| Total assets | $12.01M | $14.99M | $8.02M | $12.29M | $8.99M | $8.79M | $6.86M | $9.72M |
| Current liabilities | $4.24M | $4.78M | $4.17M | $4.62M | $4.20M | $5.32M | $5.80M | $4.79M |
| Total liabilities | $9.39M | $10.80M | $4.66M | $5.23M | $4.91M | $6.13M | $6.41M | $5.47M |
| Shareholders' equity | $2.62M | $4.19M | $3.36M | $7.06M | $4.08M | $2.66M | $452,028 | $4.24M |
| Shares outstanding | 6.21M | 4.67M | 3.92M | 3.42M | 2.90M | 1.72M | 14.62M | 966,712 |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.20M | -$3.03M | -$3.99M | -$3.66M | -$4.44M | -$2.95M | -$2.85M | -$4.42M |
| Capital expenditure | $1,792 | — | — | $3,589 | $0 | $17,331 | $259,652 | $14,907 |
| Free cash flow | -$3.20M | — | — | -$3.66M | -$4.44M | -$2.97M | -$3.11M | -$4.44M |
| Investing cash flow | -$1,792 | — | — | -$3,589 | $0 | -$17,331 | -$259,652 | -$14,907 |
| Financing cash flow | $419,249 | $10.16M | -$1,813 | $7.19M | $4.96M | $4.83M | $105,692 | -$3,277 |
| Depreciation & amortization | $67,112 | $70,000 | $70,000 | $75,078 | $75,140 | $75,009 | $66,681 | $37,062 |
| Stock-based compensation | $90,367 | $93,281 | $548,590 | $11,479 | -$211,279 | $122,641 | $204,533 | $113,079 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.